Donepezil Hydrochloride
Product Images NDC 33261-817

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 33261-817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural (Donepezil HCl 10mg Tab For Pliva 1)

Chemical structure of Donepezil Hydrochloride, showing the molecular framework including methoxy groups, a piperidine ring, and a benzyl moiety attached to the core structure.*

FDA Label Image

Donepezil Hydrochloride Figure 9 (Donepezil HCl 10mg Tab For Pliva 10)

This line graph compares the mean change from baseline in ADCS-ADL scores over 6 months between Donepezil hydrochloride 10 mg/day and placebo groups. The y-axis shows mean change with standard error, indicating clinical improvement or decline, and the x-axis represents time in months. Donepezil shows less decline compared to placebo over time.*

FDA Label Image

Donepezil Hydrochloride Figure 10 (Donepezil HCl 10mg Tab For Pliva 11)

A cumulative percentage of patients chart comparing placebo and Donepezil Hydrochloride 10 mg/day responses, showing change from baseline on the x-axis and cumulative percentage of patients on the y-axis.*

FDA Label Image

Image Label (Donepezil HCl 10mg Tab For Pliva 12)

Packaging label for Donepezil HCL 10 mg tablets by Aidarex Pharmaceuticals LLC. The label indicates 30 film-coated tablets per package, with generic name Aricept. The NDC is 33261-0817-30, and the manufacturer is Pliva Hrvatska D.O.O. Croatia. The label includes dispensing cautions and the pill description as a yellow round tablet with imprint TEVA on one side and 739 on the reverse.*

FDA Label Image

Donepezil Hydrochloride Figure 1 (Donepezil HCl 10mg Tab For Pliva 2)

A line graph depicting mean (± SE) change from baseline ADAS-cog rating over 30 weeks of drug treatment for Donepezil Hydrochloride at 5 mg/day, 10 mg/day, and placebo groups. The graph shows clinical improvement in the Donepezil groups compared to clinical decline in the placebo group over time.*

FDA Label Image

Donepezil Hydrochloride Figure 2 (Donepezil HCl 10mg Tab For Pliva 3)

A cumulative percentage graph showing patients' change from baseline in ADAS-cog scores across treatment groups for Donepezil Hydrochloride at 5 mg and 10 mg doses compared to placebo. The X-axis represents change from baseline, and the Y-axis shows cumulative percentage of patients. A table within the graph summarizes the percentage of patients with changes of -7, -4, and 0 in ADAS-cog scores by treatment group.*

FDA Label Image

Donepezil Hydrochloride Figure 3 (Donepezil HCl 10mg Tab For Pliva 4)

A bar chart showing the distribution of patients' CIBIC plus ratings across placebo, 5 mg/day, and 10 mg/day Donepezil Hydrochloride treatment groups. The X-axis categorizes patient outcomes from Markedly Improved to Markedly Worse, while the Y-axis indicates the percentage of patients in each category, illustrating comparative effects by dosage.*

FDA Label Image

Donepezil Hydrochloride Figure 4 (Donepezil HCl 10mg Tab For Pliva 5)

A line graph showing the mean change from baseline ADAS-cog ratings over 15 weeks comparing placebo, 5 mg/day, and 10 mg/day dosage groups. The x-axis represents weeks of drug treatment and placebo phase, while the y-axis quantifies clinical improvement and decline. Data points include error bars representing standard error.*

FDA Label Image

Donepezil Hydrochloride Figure 5 (Donepezil HCl 10mg Tab For Pliva 6)

A cumulative percentage of patients graph showing change from baseline on the x-axis and cumulative percentage on the y-axis. It compares placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg groups. A table within the graph shows percentages of patients with changes of -7, -4, or 0 in ADAS-cog scores by treatment group.*

FDA Label Image

Donepezil Hydrochloride Figure 6 (Donepezil HCl 10mg Tab For Pliva 7)

A bar chart showing the percentage of patients by CIBIC plus Rating categories comparing Placebo, 5 mg/day, and 10 mg/day groups. Categories on the x-axis range from Markedly Improved to Markedly Worse, and the y-axis represents percentages from 0 to 50%.*

FDA Label Image

Donepezil Hydrochloride Figure 7 (Donepezil HCl 10mg Tab For Pliva 8)

A line graph showing the mean change from baseline in SIB score over 24 weeks for Donepezil hydrochloride 10 mg/day versus placebo. The x-axis represents weeks (0, 12, 24), and the y-axis shows mean change from baseline with clinical improvement above and clinical decline below the baseline. Donepezil shows an increase in SIB score at 12 and 24 weeks, while placebo shows a decline.*

FDA Label Image

Donepezil Hydrochloride Figure 8 (Donepezil HCl 10mg Tab For Pliva 9)

A cumulative percentage of patients graph comparing placebo and Donepezil hydrochloride 10 mg/day treatment groups. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. Two curves display patient response trends over time for placebo and Donepezil hydrochloride 10 mg/day groups, respectively.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.